Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 27 Nov 2017 Status changed from active, no longer recruiting to completed.
- 27 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Aug 2017 Planned primary completion date changed from 21 Aug 2017 to 31 Dec 2017.